TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18636998

Group type: EXPERIMENTAL
Intervention: Personalized sexual behavior counseling sessions (2 sessions + 3 telephone booster sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual addiction treatment (control group)
Number of subjects: 0
Study: 16613263

Group type: EXPERIMENTAL
Intervention: Danzhi Xiaoyao powder (DXP)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Maprotiline (WMG)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both DXP and maprotiline
Number of subjects: 63
Study: 12756578

Group type: EXPERIMENTAL
Intervention: Complete vitrectomy with silicone oil endotamponade
Number of subjects: 24

Group type: COMPARATOR
Intervention: Core vitrectomy alone
Number of subjects: 24
Study: 10660730

Group type: EXPERIMENTAL
Intervention: Chemotherapy based on evidence-based medicine (EBM)
Number of subjects: 0
Study: 9138996

Group type: EXPERIMENTAL
Intervention: Ultrasonographic and echocardiographic studies
Number of subjects: 11

Group type: COMPARATOR
Intervention: Measurements (CC, CA, HA, (CA‐HA) x 100/CA)
Number of subjects: 11
Study: 1827010

Group type: EXPERIMENTAL
Intervention: Isradipine 1.25 to 2.5 mg twice daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 6291439

Group type: EXPERIMENTAL
Intervention: Conjugated estrogen therapy (0.6 mg/d)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo and low-dose treatment groups
Number of subjects: 37
Study: 31144829

Group type: EXPERIMENTAL
Intervention: Clear video with culprit-present lineup
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Degraded video with culprit-present lineup
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Clear video with culprit-removed lineup
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Degraded video with culprit-removed lineup
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Clear video with noise-degraded lineup
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Noise-degraded video with culprit-present lineup
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Noise-degraded video with culprit-removed lineup
Number of subjects: 472
Study: 28676065

Group type: COMPARATOR
Intervention: TAVI performed with prior balloon valvuloplasty (control arm)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Direct implantation of the valve (test arm)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Direct implantation of the new-generation balloon-expandable SAPIEN 3 valve
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Subgroup analysis of neurological ischemic events with cerebral MRI imaging
Number of subjects: 240
Study: 24385387

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control (no trastuzumab)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Trastuzumab and lapatinib after BM
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 132
Study: 23891167

Group type: EXPERIMENTAL
Intervention: Navigated group using navigation software
Number of subjects: 41

Group type: COMPARATOR
Intervention: Non-navigated group using surgeon judgement
Number of subjects: 41
Study: 20340011

Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg/d)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Citalopram (20-40 mg/d)
Number of subjects: 240
Study: 19056706

Group type: EXPERIMENTAL
Intervention: Vitamin/nutriceutical formulation (folate, vitamin B12, alpha‐tocopherol, S‐adenosyl methionine, N‐acetyl cysteine, and acetyl‐L‐carnitine)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vitamin/nutriceutical formulation
Number of subjects: 12
Study: 19255453

Group type: EXPERIMENTAL
Intervention: Strength protocol (3 sets of 5 repetitions at 90% of 1-RM with 3 min rest)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Hypertrophy protocol (3 sets of 10 repetitions at 70% with 1 min of rest)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Power protocol (3 sets of 5 repetitions at 50% with 3 min of rest)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Familiarization session (session RPE measured at 5-min intervals for 30 min postexercise)
Number of subjects: 15
Study: 15026402

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HTS) - 250 mL of 7.5% saline
Number of subjects: 229

Group type: COMPARATOR
Intervention: Control - 250 mL of Ringer's lactate solution
Number of subjects: 229
Study: 11463161

Group type: EXPERIMENTAL
Intervention: Methimazol (MMI)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: LAROTABE
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: MMI plus LAROTABE
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 56
Study: 9664090

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily at bedtime for 12 weeks
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 7927227

Group type: EXPERIMENTAL
Intervention: Emergency portacaval shunt
Number of subjects: 43

Group type: COMPARATOR
Intervention: Emergency medical therapy (intravenous vasopressin and esophageal balloon tamponade) followed by elective portacaval shunt
Number of subjects: 43

Group type: COMPARATOR
Intervention: Emergency medical therapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Emergency medical therapy followed by elective shunt
Number of subjects: 43
Study: 3056505

Group type: EXPERIMENTAL
Intervention: 1‐mg gemeprost (Cervagem) pessary
Number of subjects: 78

Group type: COMPARATOR
Intervention: Lamicel tent
Number of subjects: 78
Study: 31694122

Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation training and routine therapy
Number of subjects: 210

Group type: COMPARATOR
Intervention: Routine treatment only (physical therapy and NSAIDs)
Number of subjects: 210
Study: 28339432

Group type: EXPERIMENTAL
Intervention: Bipolar intraarticular pulsed radiofrequency (IAPRF) with 45 V voltage, 2 Hz frequency, 42° C temperature, 10 msec pulse width, and 10 minute duration
Number of subjects: 100

Group type: COMPARATOR
Intervention: Unipolar intraarticular pulsed radiofrequency (IAPRF) with 45 V voltage, 2 Hz frequency, 42° C temperature, 10 msec pulse width, and 10 minute duration
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bipolar intraarticular pulsed radiofrequency (IAPRF)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Unipolar intraarticular pulsed radiofrequency (IAPRF)
Number of subjects: 100
Study: 25365130

Group type: EXPERIMENTAL
Intervention: Hypnotizability (high vs low)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative suggestion about performance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive suggestion about performance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prehypnotic suggestion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Feedback suggestion during encoding or retrieval
Number of subjects: 0
Study: 22913474

Group type: EXPERIMENTAL
Intervention: CRT-ICD
Number of subjects: 1271

Group type: COMPARATOR
Intervention: ICD
Number of subjects: 1271

Group type: EXPERIMENTAL
Intervention: CRT-ICD (LBBB subgroup)
Number of subjects: 1271

Group type: COMPARATOR
Intervention: ICD (non-LBBB group)
Number of subjects: 1271
Study: 20846961

Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation
Number of subjects: 75

Group type: COMPARATOR
Intervention: Centre-based cardiac rehabilitation
Number of subjects: 75
Study: 18165563

Group type: EXPERIMENTAL
Intervention: Mirtazapine plus dexamethasone (group M + D)
Number of subjects: 80
Study: 16879679

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Suprapubic urethral support sling (SPARC)
Number of subjects: 301
Study: 12911659

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 14
Study: 10881615

Group type: EXPERIMENTAL
Intervention: Determinate spatial descriptions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indeterminate spatial descriptions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temporal descriptions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recognition test with manipulated similarity between foils and original descriptions
Number of subjects: 0
Study: 9108457

Group type: EXPERIMENTAL
Intervention: GM‐CSF gene‐transduced vaccines
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nontransduced vaccines
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: GM‐CSF gene‐transduced vaccine
Number of subjects: 16
Study: 8254871

Group type: EXPERIMENTAL
Intervention: PCEA-P group (n = 10): epidural pethidine plus 0.25% bupivacaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: PCEA-B group (n = 10): epidural buprenorphine plus 0.25% bupivacaine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PCEA-P and PCEA-B
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PCEA-P
Number of subjects: 20
Study: 2860136

Group type: EXPERIMENTAL
Intervention: Propranolol, 20 to 30 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lorazepam, 2 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 30188941

Group type: EXPERIMENTAL
Intervention: Trustworthy face
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untrustworthy face
Number of subjects: 0

Group type: COMPARATOR
Intervention: Upside down faces
Number of subjects: 0
Study: 27473327

Group type: EXPERIMENTAL
Intervention: Device-entered self-monitoring method using an activity tracker
Number of subjects: 64

Group type: COMPARATOR
Intervention: User-entered self-monitoring method (manual recording)
Number of subjects: 64
Study: 23992231

Group type: EXPERIMENTAL
Intervention: 10% concentrated sodium chloride (CSC)
Number of subjects: 72

Group type: COMPARATOR
Intervention: 3125 U/mL heparin saline (HS)
Number of subjects: 72
Study: 22066790

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/day
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg/day
Number of subjects: 485

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Number of subjects: 485
Study: 20808854

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) and L-carnitine for 6 months
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) and L-carnitine for 12 months (post-hoc analysis)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Treatment group (VPA and L-carnitine)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Age factor in treatment
Number of subjects: 61
Study: 17656831

Group type: EXPERIMENTAL
Intervention: Visual biofeedback tracking training (VBTT) for 39 minutes/day, 5 days/week, for 4 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 10
Study: 15601808

Group type: EXPERIMENTAL
Intervention: Fexofenadine given 1 hour after alfentanil followed by a meal containing orange or apple juice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fexofenadine given 1 hour after alfentanil followed by a meal not containing citrus or apple products
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alfentanil alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fexofenadine alone
Number of subjects: 0
Study: 12099628

Group type: EXPERIMENTAL
Intervention: Natural cycle IVF
Number of subjects: 1800

Group type: COMPARATOR
Intervention: IVF with ovarian stimulation
Number of subjects: 1800
Study: 10449882

Group type: EXPERIMENTAL
Intervention: Healthy children
Number of subjects: 400

Group type: COMPARATOR
Intervention: Children with congenital heart disease
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Variables dependent on vagal tone (rMSSD, pNN50, HF)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: SDNN and SDANNi
Number of subjects: 400
Study: 7600115

Group type: EXPERIMENTAL
Intervention: Growth hormone (2 IU.m‐2.d‐1)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Insulin-like growth factor-I (80 micrograms.kg‐1.d‐1)
Number of subjects: 11
Study: 2145790

Group type: COMPARATOR
Intervention: Inhaled albuterol (A) alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled albuterol (A) plus ipratropium bromide (IB)
Number of subjects: 12
Study: 1130891

Group type: EXPERIMENTAL
Intervention: Packed red cells
Number of subjects: 294

Group type: COMPARATOR
Intervention: Whole blood
Number of subjects: 294
Study: 30685489

Group type: EXPERIMENTAL
Intervention: Laparoscopic pancreatoduodenectomy
Number of subjects: 105

Group type: COMPARATOR
Intervention: Open pancreatoduodenectomy
Number of subjects: 105
Study: 28885348

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 134
Study: 25925992

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg plus UFH
Number of subjects: 108

Group type: COMPARATOR
Intervention: Standard peri-procedural UFH
Number of subjects: 108
Study: 24120550

Group type: EXPERIMENTAL
Intervention: HIV-v (250 μg or 500 μg, either alone or adjuvanted with ISA-51)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: HIV-v (high adjuvanted dose)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: HIV-v (in responding subjects)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 22143997

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 50 mg/day
Number of subjects: 1569

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 150 mg/day
Number of subjects: 1569

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 300 mg/day
Number of subjects: 1569

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1569

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 50 mg/day and 150 mg/day
Number of subjects: 1569
Study: 19808134

Group type: EXPERIMENTAL
Intervention: Roxithromycin 300 mg once daily for 3 months
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo once daily for 3 months
Number of subjects: 31
Study: 16686768

Group type: EXPERIMENTAL
Intervention: Laparoscopic donor nephrectomy
Number of subjects: 122

Group type: COMPARATOR
Intervention: Open donor nephrectomy
Number of subjects: 122
Study: 15367476

Group type: EXPERIMENTAL
Intervention: Brief advice about safe sex and complementary resources from family physicians (FPs)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Usual care (CONTROL group)
Number of subjects: 312
Study: 11116754

Group type: EXPERIMENTAL
Intervention: Clarithromycin (250 mg) co-administered with tolbutamide (500 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Tolbutamide (500 mg) alone
Number of subjects: 9
Study: 9200247

Group type: EXPERIMENTAL
Intervention: Imagery and verbal labeling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imagery
Number of subjects: 0

Group type: COMPARATOR
Intervention: No rehearsal strategy (control condition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guided movement
Number of subjects: 0
Study: 8371129

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg iv loading dose followed by 1 mg/hour continuous infusion for the treatment period)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chlorpromazine (60 mg/m2/day by continuous infusion for the same period, maximum 8 days)
Number of subjects: 40
Study: 3524334

Group type: EXPERIMENTAL
Intervention: R3: rifampin plus streptomycin plus isoniazid plus pyrazinamide daily for 3 months
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: R5: rifampin plus streptomycin plus isoniazid plus pyrazinamide daily for 3 months followed by streptomycin plus isoniazid plus pyrazinamide twice weekly for 2 months
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: Z5: the same as regimen R5 but without rifampin
Number of subjects: 694

Group type: COMPARATOR
Intervention: R3
Number of subjects: 694

Group type: COMPARATOR
Intervention: R5
Number of subjects: 694

Group type: COMPARATOR
Intervention: Z5
Number of subjects: 694

Group type: COMPARATOR
Intervention: R3 and R5 combined
Number of subjects: 694
Study: 30453599

Group type: EXPERIMENTAL
Intervention: Inpatient physiotherapy (InPhysio)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Home-based physiotherapy (HomePhysio)
Number of subjects: 104
Study: 27912741

Group type: EXPERIMENTAL
Intervention: Healthy Kiosk and nutritional education (KSEAN)
Number of subjects: 1655

Group type: EXPERIMENTAL
Intervention: Optimized physical activity (AFSO)
Number of subjects: 1655

Group type: EXPERIMENTAL
Intervention: Healthy Kiosk and nutritional education (KSEAN) + optimized physical activity (AFSO)
Number of subjects: 1655

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1655
Study: 24770985

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (4 group and 4 individual sessions) integrating risk reduction counseling with counseling to foster self-acceptance
Number of subjects: 96

Group type: COMPARATOR
Intervention: Enhanced standard of care (ESOC)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 96
Study: 22723583

Group type: EXPERIMENTAL
Intervention: Intensive glycemia (achieved median A1C of 6.4%)
Number of subjects: 7287

Group type: COMPARATOR
Intervention: Standard glycemia (achieved median A1C of 7.5%)
Number of subjects: 7287

Group type: EXPERIMENTAL
Intervention: Intensive glycemia
Number of subjects: 7287

Group type: COMPARATOR
Intervention: Standard glycemia
Number of subjects: 7287
Study: 20012449

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Experimental (EXP)
Number of subjects: 16
Study: 17196413

Group type: EXPERIMENTAL
Intervention: Theophylline treatment (0.2g, orally, q 12h for 1 month)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Theophylline treatment
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (no theophylline treatment)
Number of subjects: 37
Study: 15975303

Group type: EXPERIMENTAL
Intervention: Modified Sinisan (SNS)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Cisapride (Control)
Number of subjects: 47
Study: 12053585

Group type: EXPERIMENTAL
Intervention: one lancet-multiple pricks (multiple test method)
Number of subjects: 52

Group type: COMPARATOR
Intervention: one lancet-one prick (single test method)
Number of subjects: 52
Study: 10333620

Group type: COMPARATOR
Intervention: Cimetidine alone (group A)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combination of cimetidine and levamisole (group B)
Number of subjects: 48
Study: 8600545

Group type: EXPERIMENTAL
Intervention: rhIL-3 (2.5 or 5.0 microg/kg/d) administered by subcutaneous injection for either 5 or 10 days following ABMT.
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: rhGM-CSF (250 microg/m2/d as a 2-hour intravenous infusion) administered 24 hours after the last dose of rhIL-3.
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Sequential cytokine therapy (rhIL-3 and rhGM-CSF) post-ABMT.
Number of subjects: 37
Study: 2010560

Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verapamil 480 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (0 mg)
Number of subjects: 0
Study: 6952281

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30996366

Group type: EXPERIMENTAL
Intervention: Direct Anterior Approach (DAA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Anterolateral Approach (ALA)
Number of subjects: 50
Study: 28837727

Group type: EXPERIMENTAL
Intervention: Resonant voice training using nasal consonants (n = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Straw phonation (n = 10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 30
Study: 26309133

Group type: EXPERIMENTAL
Intervention: Full-mouth non-surgical treatment (FM-SRP)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Quadrant scaling (Q-SRP)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both FM-SRP and Q-SRP
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: FM-SRP
Number of subjects: 38
Study: 23208319

Group type: EXPERIMENTAL
Intervention: Closed suctioning (CS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Open suctioning (OS)
Number of subjects: 15
Study: 21737129

Group type: EXPERIMENTAL
Intervention: Intensive Care intervention
Number of subjects: 203

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 203

Group type: COMPARATOR
Intervention: Non-carriers
Number of subjects: 203
Study: 19564319

Group type: EXPERIMENTAL
Intervention: Therapeutic allopurinol (500 mg intravenously)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: COMPARATOR
Intervention: Subtherapeutic allopurinol
Number of subjects: 53
Study: 16972973

Group type: EXPERIMENTAL
Intervention: Intravenous frusemide 2 mg/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 50
Study: 15610084

Group type: EXPERIMENTAL
Intervention: Omeprazole, amoxycillin and metronidazole (7-day course)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 11716834

Group type: EXPERIMENTAL
Intervention: Natural movements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Scrambled displays
Number of subjects: 0
Study: 9419915

Group type: EXPERIMENTAL
Intervention: NIDCAP trained nursing staff
Number of subjects: 25
Study: 8329287

Group type: EXPERIMENTAL
Intervention: 600 mg racemic ibuprofen (RAC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 400 mg (S)-ibuprofen (S-IBU)
Number of subjects: 50
Study: 2883047

Group type: EXPERIMENTAL
Intervention: Nova T
Number of subjects: 1738

Group type: COMPARATOR
Intervention: TCu 200 Ag
Number of subjects: 1738
Study: 31386103

Group type: EXPERIMENTAL
Intervention: CURRENT AS risk score (developed from a derivation set of N=849)
Number of subjects: 1274

Group type: EXPERIMENTAL
Intervention: CURRENT AS risk score (validation set of N=425)
Number of subjects: 1274